NewEdge Advisors’s INmune Bio INMB Stock Holding History

NewEdge Advisors’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,000	Closed	-$5.65K	–	4290
2026 Q1	$5.65K	Hold	5,000	–	–	﹤0.01%	3555
2025 Q4	$7.8K	Hold	5,000	–	–	﹤0.01%	3541
2025 Q3	$10.3K	Hold	5,000	–	–	﹤0.01%	3316
2025 Q2	$11.6K	Hold	5,000	–	–	﹤0.01%	3160
2025 Q1	$39K	Hold	5,000	–	–	﹤0.01%	2632
2024 Q4	$23.4K	Hold	5,000	–	–	﹤0.01%	2765
2024 Q3	$26.9K	Sell	5,000 -5,475	-52%	-$38.9K	﹤0.01%	2632
2024 Q2	$92.4K	Hold	10,475	–	–	﹤0.01%	2145
2024 Q1	$123K	Buy	10,475 +50	+0.5%	+$604	﹤0.01%	2005
2023 Q4	$117K	Buy	10,425 +5,000	+92%	+$41.9K	﹤0.01%	1895
2023 Q3	$36.7K	Buy	+5,425	New	+$45K	﹤0.01%	2187

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors's INMB Position: Q2 2026 in Review

NewEdge Advisors sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 5,000 shares — an estimated $5.65K sold.

NewEdge Advisors first reported a position in INMB in Q3 2023 and held it in 11 quarters. The position peaked at $123K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

NewEdge Advisors reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 5,000 INmune Bio shares in Q2 2026, an estimated $5.65K.
NewEdge Advisors first reported a position in INmune Bio in Q3 2023 and held it in 11 quarters.
NewEdge Advisors's INmune Bio position peaked at $123K in Q1 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.